Introduction Chronic kidney disease (CKD) is a significant public health problem, with rising
incidence and prevalence worldwide, and is associated with increased morbidity and …

Background Chronic kidney disease (CKD) is a progressive condition that leads to
irreversible damage to the kidneys and is associated with an increased incidence of …

Introduction Chronic kidney disease (CKD) creates a significant economic burden on
patients and society. The DAPA-CKD trial reports the benefit of dapagliflozin in CKD …

Abstract Aims/Introduction Diabetic kidney disease (DKD) is the second leading cause
(16.4%) of end‐stage renal disease in China. The current study assessed the cost …

Objectives The aim of this review is to appraise and assimilate evidence from studies that
have reported on the cost-effectiveness of screening programs for chronic kidney disease …

BACKGROUND Estimation of glomerular filtration rate using equations based on creatinine
is widely used to manage chronic kidney disease. In the UK, the Chronic Kidney Disease …

Introduction Diabetes treatment has incurred financial burden. We examined the cost–utility
of adding dapagliflozin to the standard treatment for treating type 2 diabetes (T2DM) with …

Background The prevalence of chronic kidney disease (CKD) is high in general populations
around the world. Targeted testing and screening for CKD are often conducted to help …

Introduction As novel therapies for chronic kidney disease (CKD) in type 2 diabetes mellitus
(T2DM) become available, their long-term benefits should be evaluated using CKD …

Objective: Dihydropyridine calcium channel blocker (DHP-CCBs) is an appropriate add-on
antihypertensive option for uncontrolled blood pressure diabetic hypertensive patients with …